Vasilescu et al. [46] analyzed the expression of Foxp3+ and IL-17 by immunohistochemistry as a potential target for cancer immunotherapy in resected lung adenocarcinomas. This evidence concerns the gene FOXP3 and lung adenocarcinoma.